HIGHLIGHTS
- who: Pernille Ravn and colleagues from the Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark have published the article: Myoinositol vs. Metformin in Women with Polycystic Ovary Syndrome: A Randomized Controlled Clinical Trial, in the Journal: Metabolites 2022, 1183 of 24/Nov/2022
- what: HOMA-IR and weight were unchanged during MI whereas MET had beneficial effects on weight, fasting blood glucose, and HDL cholesterol.
- how: None of the studies investigated the effect of MI vs. MET in a placebo controlled setup but several uncontrolled studies showed the beneficial effects of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.